BMRA
Biomerica Inc develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions.
Biomerica, Inc. (BMRA) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (D+). The rating has held at C+ for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.4) | D+ (1.7) | C+ (2.6) | C (2.4) | C+ (2.6) | C+ (2.5) |
| 2026-11-10 | B (3.4) | D+ (1.7) | C+ (2.6) | C+ (2.6) | C+ (2.6) | C+ (2.6) |
| 2026-11-03 | B (3.3) | D+ (1.7) | C+ (2.6) | B- (3.1) | C+ (2.7) | C+ (2.7) |
| 2026-10-27 | B (3.3) | D+ (1.7) | C+ (2.6) | B- (2.9) | C+ (2.6) | C+ (2.6) |
| 2026-10-20 | B (3.3) | D+ (1.7) | C+ (2.6) | B- (3.1) | C+ (2.6) | C+ (2.7) |